Choosing an antidepressant: Effectiveness based pharmacoeconomics

Journal of Affective Disorders

Volumn 48, Issue 2-3, 1998, Pages 125-133

  Stewart, Alan ^a  

^a 27 Gilbert Street ^*  (United Kingdom)

Author keywords

Costs; Economics; Effectiveness; SSRIs; TCAs

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DECISION MAKING; DEPRESSION; ECONOMICS, PHARMACEUTICAL; HUMANS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 0031802307     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00161-4     Document Type: Article

References (25)

1. Davis R., Wilde M.I. Sertraline: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics. 10(4):1996;409-431.
2. Donoghue J.M., Tyler A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. British Journal of Psychiatry. 168:1996;164-168.
3. Dowie, J., 1994. Decision analysis: the ethical approach to medical decision making, in: Gillon, R. (Ed.), Principles of Health Care Ethics, OUP, Oxford.
4. Forder J., Kavanagh S., Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J. Affect. Disord. 38:1996;97-111.
5. Freemantle, N., Long, A., Mason, J. et al., 1993. The treatment of depression in primary care, Effective Health Care 1993; Bulletin No. 5, School of Public Health, University of Leeds, Centre for Health Economics, University of York and Research Unit, Royal College of Physicians.
6. Harrison G. New is better. Br. Med. J. 309:1994;1280-1281.
7. Hotopf M., Lewis G., Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br. J. Psychiatry. 168:1996;404-409.
8. Kamlet M.S., Paul N., Greenhouse J., Kuffer D.J., Frank E., Wade M. Cost-utility analysis of maintenance treatment for recurrent depression. Controlled Clinical Trials. 16:1995;17-40.
9. Kavanagh, S., Forder, J., Opit, L., 1993. The cost of depression in England, PSSRU Discussion Paper 902, University of Kent at Canterbury.
10. Kind P., Sorensen J. The costs of depression. Int. Clin. Psychopharmacol. 7:1993;191-195.
11. Knapp, M.R.J., 1984. The Economics of Social Care, Macmillan, London.
12. Knapp M.R.J., Beecham J. Costing Mental Health Services. Psychological Medicine. 20:1990;893-908.
13. Mausner, J.S., Kramer, S., 1985. Epidemiology. An Introductory Text, Second Edition, W.B. Saunders Company, Philadelphia.
14. Owens D. Benefits of new drugs are exaggerated. Br. Med. J. 309:1994;1281-1282.
15. Pocock, S.J., 1981. Clinical Trials A Practical Approach. John Wiley, Chichester.
16. Preskorn, S.H., 1993. Recent pharmacological advances in antidepressant therapy for the elderly. Am. J. Med. 94, Suppl. (5A), 2S-12S.
17. Robins, L.N., Regier, D.A. (Eds.), 1991. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. Free Press, New York.
18. Sashidaran S.P., Surtees P.G., Keitman N.B., Ingham J.G., Miller P. Hospital treated and general population morbidity from affective disorders: comparison of prevalence and incidence rates. Br. J. Psychiatry. 152:1988;499-505.
19. Sclar D.A., Robison L.M., Skaer T.L.et al. Antidepressant pharmacotherapy: economic outcomes in a Health maintenance Organization. Clin. Ther. 16(4):1994;715-730.
20. Sclar D.A., Robison L.M., Skaer T.L.et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a Health maintenance Organization. J. Int. Med. Res. 23:1995;395-412.
21. Skaer T.L., Sclar D.A., Robison L.M.et al. Economic evaluation of amitriptyline, desipramine, nortriptyline and sertraline in the management of patients with depression. Curr. Ther. Res. 56(6):1995;556-567.
22. Song F., Freemantle N., Sheldon T.A.et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. 306:1993;683-687.
23. Stewart, A., 1995. Simulation Models to Compare the Costs of Using SSRIs or TCAs. Discussion Paper 1103, PSSRU.
24. Stoudemire A.R., Frank N., Hedemark M.et al. The Economic Burden of Depression. General Hospital Psychiatry. 8:1986;387-394.
25. Thompson C. Management of depression in real-life settings: knowledge gained from large-scale clinical trials. International Clinical Psychopharmacology. 9(Suppl. 3):1994;21-25.